TY - JOUR
T1 - The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample
AU - Christensen, Helen
AU - Batterham, Philip J.
AU - Mackinnon, Andrew J.
AU - Jorm, Anthony F.
AU - Mack, Holly A.
AU - Mather, Karen A.
AU - Anstey, Kaarin J.
AU - Sachdev, Perminder S.
AU - Easteal, Simon
PY - 2008
Y1 - 2008
N2 - Background. While the evidence of an association between the apolipoprotein E (APOE) *E4 allele and Alzheimer's disease is very strong, the effect of the *E4 allele on cognitive decline in the general population is more equivocal. A cross-sectional study on the lifespan effects of the *E4 allele 1 failed to find any effect of the *E4 allele on cognitive performance at ages 20-24, 40-44 or 60-64 years. Methods. In this four year follow-up study, we reexamine the effect of *E4 in the sample of 2,021 individuals, now aged 65-69 years. Results. Performance on the Mini-Mental State Examination (MMSE) was significantly poorer for *E4 homozygotes than heterozygotes or non-carriers. The effects of the *E4 genotype on cognitive decline over four years were found on the MMSE and Symbol-Digit Modalities test but only when controlling for risk factors such as head injury and education. Analyses were repeated with the exclusion of participants diagnosed with a mild cognitive disorder, with little change. Conclusion. It is possible that *E4 carriers become vulnerable to greater cognitive decline in the presence of other risk factors at 65-69 years of age.
AB - Background. While the evidence of an association between the apolipoprotein E (APOE) *E4 allele and Alzheimer's disease is very strong, the effect of the *E4 allele on cognitive decline in the general population is more equivocal. A cross-sectional study on the lifespan effects of the *E4 allele 1 failed to find any effect of the *E4 allele on cognitive performance at ages 20-24, 40-44 or 60-64 years. Methods. In this four year follow-up study, we reexamine the effect of *E4 in the sample of 2,021 individuals, now aged 65-69 years. Results. Performance on the Mini-Mental State Examination (MMSE) was significantly poorer for *E4 homozygotes than heterozygotes or non-carriers. The effects of the *E4 genotype on cognitive decline over four years were found on the MMSE and Symbol-Digit Modalities test but only when controlling for risk factors such as head injury and education. Analyses were repeated with the exclusion of participants diagnosed with a mild cognitive disorder, with little change. Conclusion. It is possible that *E4 carriers become vulnerable to greater cognitive decline in the presence of other risk factors at 65-69 years of age.
UR - http://www.scopus.com/inward/record.url?scp=48349132829&partnerID=8YFLogxK
U2 - 10.1186/1471-2318-8-14
DO - 10.1186/1471-2318-8-14
M3 - Article
SN - 1471-2318
VL - 8
JO - BMC Geriatrics
JF - BMC Geriatrics
M1 - 14
ER -